These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 32955827)

  • 21. Tagraxofusp for Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Hammond D; Pemmaraju N
    Hematol Oncol Clin North Am; 2020 Jun; 34(3):565-574. PubMed ID: 32336420
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tagraxofusp followed by combined azacitidine and venetoclax in blastic plasmacytoid dendritic cell neoplasm: A case report and literature review.
    Samhouri Y; Ursu S; Dutton N; Tanvi V; Fazal S
    J Oncol Pharm Pract; 2021 Jun; 27(4):990-995. PubMed ID: 32847479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Relapse of tagraxofusp treated blastic plasmacytoid dendritic cell neoplasm with loss of CD123 expression.
    Gulati R; Abu-Salah A; Salous T; Nassiri M
    J Hematop; 2022 Mar; 15(1):35-39. PubMed ID: 38358597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Blastic plasmacytoid dendritic cell neoplasm (BPDCN): A promising future in the era of targeted therapeutics.
    Adimora IJ; Wilson NR; Pemmaraju N
    Cancer; 2022 Aug; 128(16):3019-3026. PubMed ID: 35726525
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-Term Benefits of Tagraxofusp for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Pemmaraju N; Sweet KL; Stein AS; Wang ES; Rizzieri DA; Vasu S; Rosenblat TL; Brooks CL; Habboubi N; Mughal TI; Kantarjian H; Konopleva M; Lane AA
    J Clin Oncol; 2022 Sep; 40(26):3032-3036. PubMed ID: 35820082
    [No Abstract]   [Full Text] [Related]  

  • 26. Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm.
    Economides MP; Konopleva M; Pemmaraju N
    Ther Adv Hematol; 2019; 10():2040620719874733. PubMed ID: 31579499
    [TBL] [Abstract][Full Text] [Related]  

  • 27. First pediatric experience of SL-401, a CD123-targeted therapy, in patients with blastic plasmacytoid dendritic cell neoplasm: report of three cases.
    Sun W; Liu H; Kim Y; Karras N; Pawlowska A; Toomey D; Kyono W; Gaynon P; Rosenthal J; Stein A
    J Hematol Oncol; 2018 May; 11(1):61. PubMed ID: 29720227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.
    Pemmaraju N; Kantarjian H; Sweet K; Wang E; Senapati J; Wilson NR; Konopleva M; Frankel AE; Gupta V; Mesa R; Ulrickson M; Gorak E; Bhatia S; Budak-Alpdogan T; Mason J; Garcia-Romero MT; Lopez-Santiago N; Cesarman-Maus G; Vachhani P; Lee S; Bhatt VR; Blum W; Walter RB; Bixby D; Gojo I; Duvic M; Rampal RK; de Lima M; Foran J; Fathi AT; Hall AC; Jacoby MA; Lancet J; Mannis G; Stein AS; Mims A; Rizzieri D; Olin R; Perl A; Schiller G; Shami P; Stone RM; Strickland S; Wieduwilt MJ; Daver N; Ravandi F; Vasu S; Guzman M; Roboz GJ; Khoury J; Qazilbash M; Aung PP; Cuglievan B; Madanat Y; Kharfan-Dabaja MA; Pawlowska A; Taylor J; Tallman M; Dhakal P; Lane AA
    Blood; 2023 Feb; 141(6):567-578. PubMed ID: 36399715
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and manageable safety of tagraxofusp in blastic plasmacytoid dendritic cell neoplasm: a case series of pediatric and adolescent/young adult patients.
    Pemmaraju N; Cuglievan B; Lasky J; Kheradpour A; Hijiya N; Stein AS; Meshinchi S; Mullen CA; Angelucci E; Vinti L; Mughal TI; Pawlowska AB
    EJHaem; 2024 Feb; 5(1):61-69. PubMed ID: 38406504
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD38 and BCL2 expression guides treatment with daratumumab and venetoclax in tagraxofusp-refractory blastic plasmacytoid dendritic cell neoplasm (BPDCN) featuring dynamic loss of CD123.
    Hu X; Ediriwickrema A; Saleem A; Tan B; Pemmaraju N; Mannis GN
    Leuk Res; 2024 Apr; 139():107479. PubMed ID: 38492495
    [No Abstract]   [Full Text] [Related]  

  • 31. Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Kerr D; Zhang L; Sokol L
    Curr Treat Options Oncol; 2019 Feb; 20(1):9. PubMed ID: 30715612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel Therapeutic Approaches in Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Era of Targeted Therapy.
    Wilson NR; Konopleva M; Khoury JD; Pemmaraju N
    Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):734-740. PubMed ID: 34226167
    [TBL] [Abstract][Full Text] [Related]  

  • 33. New perspectives in genetics and targeted therapy for blastic plasmacytoid dendritic cell neoplasm.
    Zhang X; Sun J; Yang M; Wang L; Jin J
    Crit Rev Oncol Hematol; 2020 May; 149():102928. PubMed ID: 32234682
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tagraxofusp: First Global Approval.
    Syed YY
    Drugs; 2019 Apr; 79(5):579-583. PubMed ID: 30859413
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD123 and More: How to Target the Cell Surface of Blastic Plasmacytoid Dendritic Cell Neoplasm.
    Bôle-Richard E; Pemmaraju N; Caël B; Daguindau E; Lane AA
    Cancers (Basel); 2022 May; 14(9):. PubMed ID: 35565416
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Blastic Plasmacytoid Dendritic Cell Neoplasm: Progress in Cell Origin, Molecular Biology, Diagnostic Criteria and Therapeutic Approaches.
    Cheng W; Yu TT; Tang AP; He Young K; Yu L
    Curr Med Sci; 2021 Jun; 41(3):405-419. PubMed ID: 34218354
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting CD123 in blastic plasmacytoid dendritic cell neoplasm using allogeneic anti-CD123 CAR T cells.
    Cai T; Gouble A; Black KL; Skwarska A; Naqvi AS; Taylor D; Zhao M; Yuan Q; Sugita M; Zhang Q; Galetto R; Filipe S; Cavazos A; Han L; Kuruvilla V; Ma H; Weng C; Liu CG; Liu X; Konoplev S; Gu J; Tang G; Su X; Al-Atrash G; Ciurea S; Neelapu SS; Lane AA; Kantarjian H; Guzman ML; Pemmaraju N; Smith J; Thomas-Tikhonenko A; Konopleva M
    Nat Commun; 2022 Apr; 13(1):2228. PubMed ID: 35484100
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Updates in Novel Therapies for Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN).
    Economides MP; Rizzieri D; Pemmaraju N
    Curr Hematol Malig Rep; 2019 Dec; 14(6):515-522. PubMed ID: 31853773
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Breakthrough in Blastic Plasmacytoid Dendritic Cell Neoplasm Cancer Therapy Owing to Precision Targeting of CD123.
    Zanotta S; Galati D; De Filippi R; Pinto A
    Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338733
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Blastic Plasmacytoid Dendritic Cell Neoplasm, from a Dermatological Point of View.
    Di Raimondo C; Lozzi F; Di Domenico PP; Paganini C; Campione E; Galluzzo M; Bianchi L
    Int J Mol Sci; 2024 Jun; 25(13):. PubMed ID: 39000208
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.